



## **eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences**

May 2, 2022

SAN DIEGO and REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:

- Fireside Chat at 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18<sup>th</sup> at 1:35 pm EDT
- Presentation at H.C. Wainwright Global Investment Conference on May 24<sup>th</sup> at 2:00 pm EDT

A live webcast of each event will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of the webcasts will be available for 30 days following the event. For more information, please visit [investors.effector.com](https://investors.effector.com).

### **About eFFECTOR Therapeutics**

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR's STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR's product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR's lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR's inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

### **Contacts:**

#### **Investors:**

Stephanie Carrington  
ICR Westwicke  
646-277-1282  
[Stephanie.Carrington@westwicke.com](mailto:Stephanie.Carrington@westwicke.com)

#### **Media:**

Heidi Chokeir, Ph.D.  
Canale Communications  
619-203-5391  
[heidi.chokeir@canalecomm.com](mailto:heidi.chokeir@canalecomm.com)